XML 47 R35.htm IDEA: XBRL DOCUMENT v3.25.3
BUSINESS COMBINATION (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Feb. 14, 2024
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2024
BusinessCombinationAndAssetAcquisitionLineItem [Line Items]            
Common stock, shares outstanding 164,614,418 197,391,411   197,391,411   177,991,365
Transaction costs $ 7,728,681 $ 7,499,353  
Transaction costs charged to equity 229,328          
Merger transaction costs       $ 7,499,353    
Issuance of Series B preferred stock $ 3,613,000          
Earnout Shares [Member]            
BusinessCombinationAndAssetAcquisitionLineItem [Line Items]            
Earnout shares issuable 24,500,000          
Tevogen Bio [Member]            
BusinessCombinationAndAssetAcquisitionLineItem [Line Items]            
Ownership percentage 91.00%